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Abstract One third of the kidney transplants performed in the
USA come from living kidney donors. The long-term out-
come of healthy individuals who donate kidneys is mostly
excellent, although recent studies have suggested that living
donation is associated with a small absolute increase in the risk
of end stage renal failure. Much of our understanding about the
progression of kidney disease comes from experimental models
of nephron loss. For this reason, living kidney donation has long
been of great interest to renal physiologists. This review will
summarize the determinants of glomerular filtration and the
physiology that underlies post-donation hyperfiltration. We de-
scribe the ‘remnant kidney’ model of kidney disease and the
reasons why such progressive kidney disease very rarely ensues
in healthy humans following uninephrectomy. We also review
some of the methods used to determine glomerular number and
size and outline their associations.
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Introduction
The first living kidney donation was performed in 1954 [1].
Currently, more than 5000 live kidney donations are
performed annually in the USA alone [2]. Since the inception
of the practice, our knowledge of the pathophysiology of
chronic kidney disease (CKD) and its progression has greatly
advanced, based in no small part on animal experimental stud-
ies of nephron loss. In this review, we highlight renal physio-
logical and pathophysiological studies that are of special rel-
evance to living kidney donation.
The Physiology of Glomerular Filtration
Much of our understanding about the dynamics of glomerular
filtration stem from experiments performed in the Munich-
Wistar rat. The kidneys of this rat strain are endowed with
superficial surface glomeruli, permitting in vivo glomerular
micro-puncture with direct measurement of single nephron
glomerular filtration rate (SNGFR) and glomerular capillary
hydraulic pressure (PGC) [3]. Further insights into glomerular
physiology have been gained from studies of humans and
large mammals in which SNGFR and PGC were either mea-
sured indirectly or estimated [4–6].
Glomerular filtration is dependent on four factors (Fig. 1).
(1) The glomerular transcapillary hydraulic pressure (ΔP) is
the difference between the PGC and the hydraulic pressure in
Bowman’s space. PGC is maintained constant by the relative
tones of the afferent and efferent arterioles across a range of
physiological blood pressures. The ΔP favors the flow of
filtrate across the glomerular capillary. (2) The glomerular
oncotic pressure (πGC) is determined by the plasma protein
concentration in the glomerular capillary and opposes the for-
mation of filtrate. The πGC increases along the length of glo-
merular capillary as unfiltered plasma proteins become con-
centrated in a progressively contracted volume of plasma. At
any point along the glomerular capillary the difference be-
tween ΔP and πGC is the net ultrafiltration pressure (PUF).
In humans, filtration is thought to occur along the full length
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of the glomerular capillary, a state referred to as filtration
dysequilibrium. (3) Increases in renal plasma flow (RPF) aug-
ment glomerular filtration rate (GFR) by blunting the plasma
contraction-related rise in oncotic pressure that occurs along
the length of the filtering glomerular capillary. (4) The ultra-
filtration coefficient (Kf) is determined by the surface area of
filtering capillary (S) and the hydraulic permeability (k) of the
glomerular filtration barrier (Kf =S×k). In simple terms, the
Kf describes the flow of filtrate (SNGFR) that will occur at a
given ultrafiltration pressure (PUF), as described by the equa-
tion; SNGFR=Kf × (PUF). The whole kidney Kf is the sum of
the all the individual glomerular Kf values. The whole kidney
Kf may be affected by changes in either glomerular number or
volume. A range of ‘normal’ values for GFR, RPF, πGC, and
filtration fraction based on studies of living donors (pre- and
post-donation) and healthy volunteers are shown in Table 1.
Loss of Nephron Mass
Experiments performed using theMunich-Wistar rat have also
shed light on the pathophysiology of CKD progression. In
these studies, a ‘5/6 nephrectomy’ was achieved though
uninephrectomy combined with either subtotal infarction or
surgical excision of two thirds (or more) of the contralateral
kidney (Fig. 2). Subsequent glomerular micropuncture and
histological analysis of the remaining kidney revealed com-
pensatory elevation of SNGFR and increases in PGC (glomer-
ular hypertension), single nephron plasma flow and glomeru-
lar tuft volume. These rats subsequently developed progres-
sive CKD, the so-called ‘remnant kidney syndrome’, which is
characterized by systemic hypertension, proteinuria, and the
h i s t o l o g i c a l f e a t u r e s o f f o c a l a nd s egmen t a l
glomerulosclerosis (FSGS) [9, 10•]. In humans, a similar
Table 1 Reference values for






Iothalmate GFR per 1.73 m2 (n= 57)a 101±19 66±12
Inulin GFR per 1.73 m2 (n = 180)b 100±18 –
Renal plasma flow (PAH) per 1.73 m2 (n = 237)c 527±132 322±160
πAA mmHg (n= 237) 25.3±2.6 –
Filtration Fraction (n= 237) 0.2±0.04 0.21±0.03
a From reference [7], pre-operative living kidney donors, age range 23–68 years
b From reference [8], healthy volunteers, age range 18–88 years
c From references [7] and [8], pre-operative living kidney donors and healthy volunteers, age range 18–88 years
d For 26 subjects aged 57±7 years, who were 7.4±2.9 years post-donation
πAA, afferent arteriolar oncotic pressure
Fig. 1 A schematic view of glomerular ultrafiltration across the
glomerular capillary. The Starling’s forces at work are the (1)
glomerular transcapillary hydraulic pressure ΔP which is the difference
between the glomerular and Bowman’s Space hydrostatic pressures and
(2) the opposing glomerular capillary oncotic pressure (πGC). Bowman’s
Space oncotic pressure is negligible and usually disregarded. The
difference between ΔP and πGC at any given point is the net
ultrafiltration pressure (PUF). ΔP remains constant across the length of
the glomerular capillary. However, because πGC rises as plasma proteins
concentrate, the rate of ultrafiltration decreases along the length of the
capillary
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phenomenon known as secondary FSGS commonly occurs in
kidneys that have already been injured by another process,
such as reflux nephropathy [11] or, less commonly, in the
setting of obesity [12].
The pathophysiology of FSGS following the loss of neph-
ron mass has been extensively studied. It has, however, prov-
en difficult to fully disentangle the relative contributions of
glomerular hypertension, increased single nephron GFR,
compensatory glomerular hypertrophy, and other pathophysi-
ological responses to the development of glomerulopenia-
induced glomerular injury (Fig. 3).
Glomerular hypertension alone is almost certainly directly
injurious. Experimental studies in the remnant kidney model
have shown that normalization of both glomerular and systemic
hypertension with an angiotensin converting enzyme (ACE)
inhibitor or angiotensin receptor blocker, compared to normal-
ization of systemic hypertension alone using alternative antihy-
pertensive agents, is associated with attenuation of proteinuria
and FSGS [13, 14]. Institution of a low protein diet also results
in normalization of glomerular pressure and is associated with a
similar protection against renal injury [15]. Furthermore, mice
chronically treated with an angiotensin II (ATII) infusion de-
velop glomerular hypertension, proteinuria, and FSGS [16].
While these experiments do show an association between
raised glomerular pressure and renal injury they do not prove
glomerular injury is directly caused by glomerular hyperten-
sion. That being said, there are a number of biologically plau-
sible mechanisms for glomerular hypertension-induced renal
injury including (1) direct endothelial injury (barotrauma), (2)
stimulation of the mesangial cell and matrix proliferation [17],
(3) altered glomerular handling of macromolecules leading to
their aberrant mesangial deposition, (4) increased podocyte
shear stress resulting from increased flow of glomerular filtrate
and, (5) mechanical distension of the glomerular capillary ne-
cessitating increased podocyte surface area coverage.
An alternative, and not necessarily mutually exclusive,
mechanism for glomerular injury following the loss of renal
mass centers on the effect of glomerular hypertrophy on
podocyte health [16, 18–20]. Podocytes (which are terminally
differentiated cells) must enlarge to cover an expanding base-
ment membrane as glomeruli hypertrophy. This process pre-
disposes to the development of gaps between podocytes and
the direct exposure of the glomerular basement membrane
(GBM) to Bowman’s Space, a process that may initiate scle-
rosis. Subsequent glomerular loss due to FSGS may in turn
result in further hypertrophy of remaining nephrons, setting in
motion a vicious cycle of glomerular hypertrophy and further
podocyte ‘stretch’. In some experimental models, glomerular
hypertrophy alone appears sufficient to result in podocyte
death and FSGS [21]. However, glomerular hypertrophy is
especially relevant when accompanied by other pathological
processes that initiate podocyte injury and loss [19]. Indeed,
the combination of glomerular hypertrophy (following
uninephrectomy) and ATII (infusion)-mediated systemic and
glomerular hypertension results in a significantly greater de-
gree of proteinuria and glomerular sclerosis, than an ATII
infusion alone [16]. The link between glomerular hypertrophy
and accelerated kidney disease is also supported by a biopsy
study showing an association between mean glomerular tuft
area and subsequent development of FSGS in patients with
minimal change disease [22].
Fig. 2 The ‘remnant kidney model’. A 5/6 nephrectomy is achieved
through unilateral nephrectomy plus either (1) surgical amputation of
the superior and inferior poles of the remaining kidney or (2) ligation of
two out of three branches of the renal artery resulting in infarction of two-
thirds of the remaining kidney
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Glomerular hypertrophy occurs rapidly after nephron
loss in experimental animal studies [23]. However, the
mechanism for ‘compensatory’ glomerular enlargement
is not fully understood. Glomerular volume is likely in-
fluenced by metabolic workload. For instance, experi-
mental manipulation of diet leads to significant alter-
ations in glomerular volume; both high protein and high
salt diets result in increased glomerular volume, while
post-nephrectomy glomerular hypertrophy can be
prevented by protein restriction [19, 24, 25]. The influ-
ence of metabolism and workload on glomerular volume
is further evidenced by the strong correlation between
body surface area and glomerular volume in humans
[26•]. A number of putative ‘renotrophic factors’ have
been proposed, including insulin-like growth factor, epi-
dermal growth factor, hepatocyte growth factor, and ATII
[27, 28]. ATII does seem to be required for normal glo-
merular growth during development [28]. However,
chronic ATII infusion does not result in glomerular hy-
pertrophy, and the glomerular hypertrophy induced by a
high-protein diet is not prevented by ACE inhibition [16,
24]. Direct mechanical stretch resulting from glomerular
hypertension may also induce capillary distension and
mesangial cell and matrix proliferation [17]. Regardless
of its underlying mechanism, nitric oxide-mediated vaso-
dilation, and hyperperfusion of the remaining nephrons
appears to be required for ‘normal’ renal hypertrophy to
occur following nephrectomy [29].
Fig. 3 Potential pathways toward
the development of focal
segmental glomerulosclerosis
(FSGS) following loss of nephron
mass. PGC glomerular capillary
hydrostatic pressure, ATII
angiotensin II, TGFβ
transforming growth factor beta
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ACE inhibitors and ATII receptor blockers exert a protec-
tive effect in the remnant kidneymodel [9, 14]. There has been
much work examining potential non-hemodynamic role(s) for
ATII in the pathogenesis of FSGS. Angiotensin II in certain
circumstances may directly injure podocytes. Overexpression
of ATII receptors in podocytes is associated with their dys-
function and loss [20]. Moreover, in 5/6 nephrectomized rats,
ATII blockade is associated with reduced podocyte injury and
loss [30]. In addition, ATII exposure results in increased
mesangial cell production of the pro-fibrotic cytokine TGFβ
in vitro, while ATII administration is associated with en-
hanced glomerular TGFβ expression in otherwise healthy rats
in vivo [31]. Furthermore, enhanced TGFβ expression occurs
in concert with ATII expression in rat glomeruli following 5/6
nephrectomy and ATII receptor blockade significantly reduces
post-5/6 nephrectomy glomerular TGFβ expression [32, 33].
The process of secondary FSGS in the remnant kidney is also
accompanied by inflammation and it is likely, as with many
pathophysiological processes, that a dysregulated immune re-
sponse may exacerbate tissue injury [34].
Post-Donation Glomerular Physiology
In humans there are rapid parallel increases in RPF and single
kidney GFR following kidney donation, such that GFR falls to
70 % rather than 50 % of its pre-donation level [35]. The early
increase in RPF results, at least in part, from nitric oxide-
mediated vasodilation [29]. However, an increase in kidney
volume of around 30 % [36, 37] also occurs post-donation,
which presumably reflects underlying glomerular hypertrophy.
Our recent study reported on serial physiological and radiolog-
ical measurements in 21 living kidney donors followed to a
median of 6.3 years post-donation. Mathematically modeled
glomerular ultrafiltration dynamics were studied at pre-, early-,
and late-post-donation time points. The final model, which
assumed that post-donation whole kidney Kf increased in pro-
portion to renocortical volume, suggested that post-donation
hyperfiltration could be entirely attributed to enhanced glomer-
ular ultrafiltration capacity, without any measurable contribu-
tion by glomerular capillary hypertension [37].
Nephron Number and Glomerular Volume
Nephron number in adult humans is highly variable but has
been estimated to average 600,000 per kidney [26•]. Nephron
number has a positive correlation with birth weight [38], and
congenitally low nephron endowment has been proposed as a
risk factor for the development of hypertension and renal dis-
ease, the so called “Brenner hypothesis” [39].
GFR decreases with age, at an average rate of −0.75 mls/
min /1 .73 m2/yea r [40 ] . In pa ra l l e l , age - re l a t ed
glomerulosclerosis, traditionally attributed to intrarenal vascu-
lar disease, increases with age [41, 42]. Autopsy studies of
nephron number, such as that of Nyengaard et al., that have
counted glomeruli irrespective of whether they are open or
sclerosed and have shown a decline in total glomerular num-
ber with age suggesting that a proportion of glomeruli are
ultimately reabsorbed and effectively disappear [26•]. The in-
verse correlation between age and glomerular number has also
been demonstrated in living donors [7]. The relation between
glomerular volume and age is much less clear. However, stud-
ies that have excluded sclerosed or involuting glomeruli show
a positive correlation between glomerular volume and age
[43]. Hypertension may contribute to nephron loss or may
be a product of congenital low nephron number. Some studies
have suggested that hypertension is associated with low neph-
ron number and large glomerular volume, with differing con-
clusions, likely, in part, reflecting differences in the popula-
tions studied [44–46].
The gold standard for the estimation of glomerular number
is the fractionator-dissector method in which a random unbi-
ased (but known) fraction of kidney sections is selected for
counting (for a detailed description of the methods see refer-
ences [26•, 47]). Within each sampled section a counting grid
is superimposed and glomeruli within that area (a known frac-
tion of the kidney) are counted. Each counting grid contains
two adjacent ‘inclusion’ and ‘exclusion’ lines such that ob-
jects touching the inclusion and exclusion lines are counted
and not counted, respectively. For each sampled section the
succeeding ‘look-up’ section is selected and the same
counting frame is identified within that section. Only glomer-
uli identified in the sampled section but not the look-up sec-
tion are counted. The relative fractions of cortical area and
glomerular area in each section are calculated using point
counting. The volume fraction of glomeruli (Vvglom/cor) is
the proportion of the sampled area that contains glomeruli
divided by the proportion that contains cortex. The numerical
density of glomeruli in the cortex (Nvglom/cor) is calculated
as the total number of glomeruli counted divided by the total
cortical volume of the sampled sections (calculated as the
proportion of the sampled area that contains cortex× sampled
area× section thickness). The mean glomerular volume is then
derived by dividing the Vvglom by the Nvglom. The major
disadvantage of this method is that it requires a whole kidney,
is labor intensive, and requires consistent and expert tissue
processing capabilities. In addition, the calculation of mean
glomerular volume will not take into account variation in glo-
merular volume within a kidney.
Glomerular volume can also be measured directly. The
gold standard for direct volume measurement uses the
Cavalieri principle, which requires no assumptions about the
shape of the glomerulus but requires measurement of multiple
serial sections of the same glomerulus [48]. Other methods
such as that of Weibel and Gomez, assume the glomerulus is
spherical, allowing the mean glomerular area to be calculated
from multiple glomeruli (usually > 20) measured through
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random planar sections [49]. Alternatively, the identification
of and measurement of the maximum planar area of a glomer-
ulus through examination of serial sections is significantly less
work than the Cavalieri method but also requires the assump-
tion of a spherical glomerulus [48].
Our group has described a method for estimating the num-
ber of functioning glomeruli using kidney biopsy data com-
bined with measurement of GFR, RPF, and plasma oncotic
pressure (Fig. 4) [7]. SNKf is a product of glomerular capillary
filtering surface area and hydraulic permeability. Filtering sur-
face area is estimated on biopsy specimens by measuring both
the volume and percentage filtering capillary surface area of
sampled glomeruli. The hydraulic permeability is estimated
from the measured GBM thickness. Whole kidney Kf is esti-
mated using a formula derived by Deen et al., using GFR,
RPF, plasma oncotic pressure, and an estimate of ΔP [50].
The number of functioning glomeruli may then be calculated
by dividing the whole kidneyKf by the single nephronKf. The
advantages of this method are that it requires only a biopsy
sample rather than one whole kidney. The major disadvantage
is that the whole kidney Kf may be influenced by transient
hemodynamic changes.
Overall, living donor outcomes are excellent. Most studies
have found no increase in all-cause or cardiovascular mortality
among donors compared either with the general population [51]
or with selected healthy non-donor controls [52–54]. However,
two recent retrospective studies have suggested, that when com-
pared to healthy controls screened to simulate donor selection,
kidney donation is associated with a small absolute increase in
the risk of end stage renal disease (ESRD) [55, 56•]. Studies of
post-donation hypertension have disclosed mixed results [57,
58]. However, a meta-analysis has shown that after a median
follow-up of 5 years, living kidney donationwas associatedwith
a 5-mmHg increase in mean arterial pressure [59].
Historically, concern regarding the outcome of living dona-
tion was driven by the huge body of animal experimental work
highlighting the adverse effects of nephron loss [60]. However,
it is now more than 60 years since the first living kidney dona-
tion and while there have been isolated reports of secondary
FSGS ensuing late post-kidney donation [60], no epidemic of a
post-donation remnant kidney-type syndrome has been identi-
fied. There are a number of potential explanations for this; 1)
the experimental models of nephrectomy likely overestimate
the risk of secondary FSGS. Most of the studies were per-
formed in the rats with quite profound nephron loss resulting
from 5/6th (or even 11/12th[10]) nephrectomy rather than
uninephrectomy. The 5/6th nephrectomy is frequently achieved
by combining uninephrectomy with ligation of two out of three
branches of the renal artery resulting in subtotal infarction of the
remaining kidney, a procedure that is associated with accentu-
ation of the disease process in the remnant kidney when com-
pared to surgical two-third nephrectomy of the remaining kid-
ney [61]. Moreover, the rat appears to be unusually susceptible
to the development of secondary FSGS. FSGS is commonly
observed following uninephrectomy in rats and is also observed
in otherwise healthy aging rats [62–64]. (2) Given the relatively
Fig. 4 Estimation of the number
of functioning nephrons. Whole
kidney Kf is calculated from
measured GFR, RPF, and plasma
oncotic pressure. Single nephron
Kf is estimated from the
histologically and
ultrastructurally-derived
estimations of filtering surface
area and hydraulic permeability in
glomeruli obtained through
kidney biopsy. The number of
functioning glomeruli is then
computed by dividing whole
kidney Kf by single kidney Kf
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short period of follow-up of humans, it is conceivable that the
remnant kidney phenomenon could ensue in a greater propor-
tion of living donors with time. This concern is especially rel-
evant in very young donors, who may reasonably expect to
enjoy another 60 years of post-donation life. (3) We infer that,
in the absence of a ‘second hit’, post-donation nephron number
is well above the threshold required for the remnant kidney
phenomenon to occur. However, certain groups such as older
donors or hypertensive donors, whose pre-donation nephron
number may be at the lower end of the normal spectrum, might
be expected over time to have a higher risk of post-donation
problems. Indeed, the effect of relative post-donation
‘glomerulopenia’ may contribute to the very small excess risk
of ESRD in older compared to younger donors [56•]. Finally,
whereas hypertensive donors have shown good renal function
and blood pressure control in the short term [65, 66], a
lack of longer term data requires that extended follow
up of hypertensive donors be undertaken to ensure their
long term well-being.
Kidney size correlates with nephron number and has been
used as a surrogate marker of nephron endowment [26•].
Smaller kidney size, especially if mismatched with recipient
size, has consistently been shown to be associated with poorer
graft function and survival in kidney transplant recipients,
who in contrast to living donors, are exposed to a myriad of
potential (ischemic, immune, toxic) ‘second hits’ [67–69].
Another concern stemming from experimental studies is
that larger pre-donation glomerular volume followed by
post-donation glomerular hypertrophy could predispose to
podocyte injury and the development of post-donation
FSGS. To our knowledge, there are no data to date linking
pre-donation glomerular volumewith kidney donor outcomes.
However, in stable kidney transplant recipients, larger glomer-
ular volume measured in early post-transplant protocol biop-
sies is associated with reduced graft survival [70].
One of the most important advances in nephrology over the
past decade has been the identification of the APOL1 genetic
risk variants and their association with the development of non-
diabetic kidney disease (including FSGS) in patients of African
ancestry [71]. The mechanism behind APOL1-associated renal
disease has not been elucidated, although the relation between
APOL1 risk variants and podocyte injury is being investigated
[72]. In the absence of kidney disease, there does not appear to
an obvious renal phenotype associated with the APOL1 risk
variant. In a recent autopsy study neither glomerular number
or volume differed according to APOL1 risk profile, although a
potential association between age-related reduction in glomer-
ular number and the APOL1 risk variant was proposed [73].
Kidney transplant survival is significantly reduced in patients
who receive a deceased donor kidney that is homozygous for
the APOL1 risk variant [74]. The outcome of living donors who
are homozygous for the APOL1 variant is unknown; however,
it is tempting to speculate that much, if not all, of the excess risk
of renal failure in African American donors may be attributable
to APOL1 risk variant [56•].
Conclusion
Historical concerns regarding the safety of living kidney do-
nation are threefold. The first concern was that the metabolic
effect of a 30 % reduction in kidney function would prove
harmful in the long-term. To date, a significant ‘uremic’ effect
associated with kidney donation has not been identified, al-
though, compensatory changes in the phosphate-PTH-FGF23
axis have been cited as evidence of CKD [58]. Secondly, the
association between nephron loss and FSGS in experimental
models raised obvious concerns about the safety of nephrec-
tomy for kidney donation in otherwise healthy humans.
Fortunately, 60 years of living kidney donation has largely
allayed fears for an epidemic of post-donation FSGS. The
final concern was (and remains) that prior uninephrectomy
may accelerate the progression of de novo post-donation kid-
ney disease. This notion is supported by animal models where
a reduction in nephron number accentuates most disease pro-
cesses in the remaining kidney [16, 18, 19]. We believe that a
careful pre-donation medical assessment remains vital and
hope that new diagnostic developments, such as apolipopro-
tein L1 G1 and G2 risk variant testing, and improved baseline
risk prediction [75] will further enhance our ability to identify
and exclude donor candidates who are at high risk of future
renal disease.
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